Endocyte, Inc. (NASDAQ:ECYT) – Analysts at Wedbush reduced their Q3 2017 earnings estimates for shares of Endocyte in a research note issued to investors on Tuesday. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings per share of ($0.51) for the quarter, down from their previous estimate of ($0.23). Wedbush has a “Outperform” rating and a $7.00 price target on the stock. Wedbush also issued estimates for Endocyte’s Q4 2017 earnings at ($0.17) EPS, FY2017 earnings at ($1.22) EPS, Q1 2018 earnings at ($0.21) EPS, Q2 2018 earnings at ($0.22) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.24) EPS, FY2018 earnings at ($0.89) EPS, FY2019 earnings at ($0.77) EPS, FY2020 earnings at ($1.31) EPS and FY2021 earnings at ($0.83) EPS.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.03). The company had revenue of $0.01 million for the quarter. Endocyte had a negative return on equity of 32.68% and a negative net margin of 61,437.14%. During the same period in the previous year, the business earned ($0.25) EPS.

ILLEGAL ACTIVITY NOTICE: “Q3 2017 EPS Estimates for Endocyte, Inc. Reduced by Analyst (ECYT)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/06/q3-2017-eps-estimates-for-endocyte-inc-reduced-by-analyst-ecyt.html.

Several other equities analysts also recently commented on the company. ValuEngine upgraded Endocyte from a “strong sell” rating to a “sell” rating in a research note on Monday. Cowen and Company reiterated a “hold” rating on shares of Endocyte in a research note on Monday. Finally, Zacks Investment Research downgraded Endocyte from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $7.00.

Shares of Endocyte (NASDAQ:ECYT) opened at 5.70 on Friday. Endocyte has a 12 month low of $1.17 and a 12 month high of $6.55. The firm’s 50-day moving average is $1.81 and its 200 day moving average is $1.91. The firm’s market capitalization is $242.68 million.

Large investors have recently bought and sold shares of the business. Teachers Advisors LLC lifted its position in shares of Endocyte by 17.1% during the fourth quarter. Teachers Advisors LLC now owns 65,119 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 9,506 shares in the last quarter. RMB Capital Management LLC lifted its position in shares of Endocyte by 8.8% during the first quarter. RMB Capital Management LLC now owns 264,885 shares of the biopharmaceutical company’s stock worth $681,000 after acquiring an additional 21,500 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Endocyte by 26.7% during the first quarter. Ameriprise Financial Inc. now owns 133,270 shares of the biopharmaceutical company’s stock worth $343,000 after acquiring an additional 28,110 shares in the last quarter. FMR LLC lifted its position in shares of Endocyte by 0.7% during the first quarter. FMR LLC now owns 3,509,035 shares of the biopharmaceutical company’s stock worth $9,018,000 after acquiring an additional 24,625 shares in the last quarter. Finally, Stifel Financial Corp lifted its position in shares of Endocyte by 3.9% during the first quarter. Stifel Financial Corp now owns 45,353 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 1,711 shares in the last quarter. Hedge funds and other institutional investors own 28.80% of the company’s stock.

About Endocyte

Earnings History and Estimates for Endocyte (NASDAQ:ECYT)

Receive News & Stock Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related stocks with our FREE daily email newsletter.